{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:38:58Z","timestamp":1740109138807,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T00:00:00Z","timestamp":1674259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"DOI":"10.1007\/s00404-023-06918-9","type":"journal-article","created":{"date-parts":[[2023,1,21]],"date-time":"2023-01-21T06:04:31Z","timestamp":1674281071000},"page":"231-237","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison end-to-end anastomosis with ostomy after secondary surgical cytoreduction for recurrent high-grade serous ovarian cancer: observational single-center study"],"prefix":"10.1007","volume":"308","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9679-0198","authenticated-orcid":false,"given":"Luka","family":"Matak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mislav","family":"Miku\u0161","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"\u0106ori\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Spagnol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Matak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goran","family":"Vuji\u0107","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,1,21]]},"reference":[{"issue":"6","key":"6918_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"issue":"2\u20133","key":"6918_CR2","first-page":"64","volume":"47","author":"K Kati\u0107","year":"2019","unstructured":"Kati\u0107 K, Matkovi\u0107 V, Le\u0161in et al (2019) First-line treatment of ovarian cancer FIGO stages IIIB-IV: focus on therapy with bevacizumab\u2014our experience. Libri Oncol 47(2\u20133):64\u201370","journal-title":"Libri Oncol"},{"key":"6918_CR3","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ijgo.12614","volume":"143","author":"JS Berek","year":"2018","unstructured":"Berek JS, Kehoe ST, Kumar L, Friedlander M (2018) Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynecol Obstet 143:59\u201378","journal-title":"Int J Gynecol Obstet"},{"key":"6918_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/01.AOG.0000192407.04428.bb","volume":"107","author":"GD Aletti","year":"2006","unstructured":"Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope RC, Wilson TO et al (2006) Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107:77\u201385","journal-title":"Obstet Gynecol"},{"key":"6918_CR5","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"SJ Chang","year":"2013","unstructured":"Chang SJ, Hodeib M, Chang J, Bristow RE (2013) Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol 130:493\u2013498","journal-title":"Gynecol Oncol"},{"issue":"2","key":"6918_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.ygyno.2016.05.035","volume":"142","author":"JH Tseng","year":"2016","unstructured":"Tseng JH et al (2016) Diverting ileostomy during primary debulking surgery for ovarian cancer: associated factors and postoperative outcomes. Gynecol Oncol\u00a0142(2):217\u2013224","journal-title":"Gynecol Oncol"},{"key":"6918_CR7","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1200\/JCO.2002.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Monts FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248\u20131259","journal-title":"J Clin Oncol"},{"issue":"1","key":"6918_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ygyno.2017.11.017","volume":"148","author":"R Tozzi","year":"2018","unstructured":"Tozzi R et al (2018) Morbidity and reversal rate of ileostomy after bowel resection during visceral-peritoneal debulking (VPD) in patients with stage IIIC-IV ovarian cancer. Gynecol Oncol 148(1):74\u201378","journal-title":"Gynecol Oncol"},{"issue":"4","key":"6918_CR9","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e60","volume":"29","author":"M Kim","year":"2018","unstructured":"Kim M, Suh DH, Park JY et al (2018) Survival impact of low anterior resection in patients with epithelial ovarian cancer grossly confined to the pelvic cavity: a Korean multicenter study. J Gynecol Oncol 29(4):e60","journal-title":"J Gynecol Oncol"},{"key":"6918_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1001\/jamaoncol.2018.2761","volume":"4","author":"RL Dood","year":"2018","unstructured":"Dood RL, Zhao Y, Armbruster SD et al (2018) Defining survivorship trajectories across patients with solid tumors: an evidence-based approach. JAMA Oncol 4:1519\u20131526","journal-title":"JAMA Oncol"},{"key":"6918_CR11","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.clon.2018.04.006","volume":"30","author":"M Bommert","year":"2018","unstructured":"Bommert M, Harter P, Heitz F, du Bois A (2018) When should surgery be used for recurrent ovarian carcinoma? Clin Oncol (R Coll Radiol) 30:493\u2013497","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"6918_CR12","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1056\/NEJMoa1902626","volume":"381","author":"RL Coleman","year":"2019","unstructured":"Coleman RL, Spirtos NM, Enserro D et al (2019) Secondary surgical cytoreduction for recurrent ovarian cancer. N Engl J Med 381:1929\u20131939","journal-title":"N Engl J Med"},{"key":"6918_CR13","doi-asserted-by":"publisher","first-page":"5501","DOI":"10.1200\/JCO.2017.35.15_suppl.5501","volume":"35","author":"A Du Bois","year":"2017","unstructured":"Du Bois A, Vergote I, Ferron G et al (2017) Randomized controlled phase III study evaluating the impact of secondary cytoreductive surgery in recurrent ovarian cancer: AGO DESKTOP III\/ENGOT ov20. J Clin Oncol 35:5501 (abstract)","journal-title":"J Clin Oncol"},{"issue":"8","key":"6918_CR14","doi-asserted-by":"publisher","first-page":"896","DOI":"10.6004\/jnccn.2019.0039","volume":"17","author":"DK Armstrong","year":"2019","unstructured":"Armstrong DK et al (2019) National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer (version 2.2018). J Natl Compr Canc Netw 17(8):896-909. https:\/\/doi.org\/10.6004\/jnccn.2019.0039","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"6918_CR15","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","volume":"14","author":"P Harter","year":"2012","unstructured":"Harter P, Heitz F, du Bois A (2012) Surgery for relapsed ovarian cancer: when should it be offered? Curr Oncol Rep 14(6):539\u2013543","journal-title":"Curr Oncol Rep"},{"unstructured":"National Comprehensive Cancer Network (NCCN) Clinical practice guidelines in ovarian cancer. Version 1.2017","key":"6918_CR16"},{"issue":"1","key":"6918_CR17","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ygyno.2013.06.020","volume":"131","author":"M Petrillo","year":"2013","unstructured":"Petrillo M, Fagotti A, Ferrandina G et al (2013) Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors. Gynecol Oncol 131(1):36\u201341","journal-title":"Gynecol Oncol"},{"issue":"12","key":"6918_CR18","doi-asserted-by":"publisher","first-page":"3955","DOI":"10.1245\/s10434-013-3091-6","volume":"20","author":"M Petrillo","year":"2013","unstructured":"Petrillo M, Ferrandina G, Fagotti A et al (2013) Timing and pattern of recurrence in ovarian cancer patients with high tumor dissemination treated with primary debulking surgery versus neoadjuvant chemotherapy. Ann Surg Oncol 20(12):3955\u20133960","journal-title":"Ann Surg Oncol"},{"key":"6918_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1097\/MD.0000000000004797","volume":"95","author":"Y Luo","year":"2016","unstructured":"Luo Y, Lee M, Kim HS et al (2016) Effect of neoadjuvant chemotherapy on platinum resistance in stage IIIC and IV epithelial ovarian cancer. Medicine 95:36","journal-title":"Medicine"},{"key":"6918_CR20","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1245\/s10434-015-4623-z","volume":"22","author":"AA da Costa","year":"2015","unstructured":"da Costa AA, Valadares CV, Baiocchi G et al (2015) Neoadjuvant chemotherapy followed by interval debulking surgery and the risk of platinum resistance in epithelial ovarian cancer. Ann Surg Oncol 22:971\u2013978","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"6918_CR21","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","volume":"13","author":"P Harter","year":"2006","unstructured":"Harter P, du Bois A, Hahmann M et al (2006) Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft gynaekologische onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13(12):1702\u20131710","journal-title":"Ann Surg Oncol"},{"issue":"2","key":"6918_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","volume":"21","author":"P Harter","year":"2011","unstructured":"Harter P, Sehouli J, Reuss A et al (2011) Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 21(2):289\u2013295","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"6918_CR23","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.ygyno.2006.05.003","volume":"103","author":"DL Richardson","year":"2006","unstructured":"Richardson DL, Mariani A, Cliby WA (2006) Risk factors for anastomotic leak after recto-sigmoid resection for ovarian cancer. Gynecol Oncol 103(2):667\u2013672","journal-title":"Gynecol Oncol"},{"issue":"2","key":"6918_CR24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ygyno.2012.04.030","volume":"126","author":"M Peiretti","year":"2012","unstructured":"Peiretti M, Bristow RE, Zapardiel I, Gerardi M, Zanagnolo V, Biffi R, Landoni F, Bocciolone L, Aletti GD, Maggioni A (2012) Rectosigmoid resection at the time of primary cytoreduction for advanced ovarian cancer. A multi-center analysis of surgical and oncological outcomes. Gynecol Oncol 126(2):220\u2013223","journal-title":"Gynecol Oncol"},{"issue":"3","key":"6918_CR25","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ygyno.2005.07.112","volume":"99","author":"SM Mourton","year":"2005","unstructured":"Mourton SM, Temple LK, Abu-Rustum NR, Gemignani ML, Sonoda Y, Bochner BH, Barakat RR, Chi DS (2005) Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol 99(3):608\u2013614","journal-title":"Gynecol Oncol"},{"issue":"9","key":"6918_CR26","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1136\/ijgc-2021-002951","volume":"31","author":"C Fotopoulou","year":"2021","unstructured":"Fotopoulou C, Planchamp F, Aytulu T, Chiva L, Cina A, Erg\u00f6n\u00fcl O et al (2021) European society of gynaecological oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery. Int J Gynecol Cancer 31(9):1199\u20131206","journal-title":"Int J Gynecol Cancer"},{"issue":"9","key":"6918_CR27","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1007\/s00384-015-2253-3","volume":"30","author":"MF Sier","year":"2015","unstructured":"Sier MF, van Gelder L, Ubbink DT, Bemelman WA, Oostenbroek RJ (2015) Factors affecting timing of closure and non-reversal of temporary ileostomies. Int J Color Dis 30(9):1185\u20131192","journal-title":"Int J Color Dis"},{"issue":"9","key":"6918_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.14740\/jocmr2150w","volume":"7","author":"P Waterland","year":"2015","unstructured":"Waterland P, Goonetilleke K, Naumann DN, Sutcliff M, Soliman F (2015) Defunctioning ileostomy reversal rates and reasons for delayed reversal: does delay impact on complications of ileostomy reversal? A study of 170 defunctioning ileostomies. J Clin Med Res 7(9):685\u2013689","journal-title":"J Clin Med Res"},{"issue":"23","key":"6918_CR29","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa2103294","volume":"385","author":"P Harter","year":"2021","unstructured":"Harter P, Sehouli J, Vergote I, Ferron G, Reuss A, Meier W et al (2021) DESKTOP III Investigators. Randomized trial of cytoreductive surgery for relapsed ovarian cancer. N Engl J Med 385(23):2123\u20132131","journal-title":"N Engl J Med"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-06918-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00404-023-06918-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-023-06918-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T12:06:56Z","timestamp":1684325216000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00404-023-06918-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,21]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["6918"],"URL":"https:\/\/doi.org\/10.1007\/s00404-023-06918-9","relation":{},"ISSN":["1432-0711"],"issn-type":[{"type":"electronic","value":"1432-0711"}],"subject":[],"published":{"date-parts":[[2023,1,21]]},"assertion":[{"value":"17 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}